Table 3.
Characteristics of patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (n = 174).
| Patients’ Characteristics | R/R FLT3-Mutated AML N = 174 |
|---|---|
| Age (years): | |
| Refractory: Median (IQR) | 57.8 (43.1–67.3) |
| Relapse: Median (IQR) | 59.9 (47.2–70.7) |
| Gender: n (%) | |
| Female | 88 (50.6) |
| Male | 86 (49.4) |
| ECOG performance status: n (%) | |
| 0–1 | 106 (79.7) |
| ≥2 | 27 (20.3) |
| Status: n (%) | |
| Refractory | 48 (27.6) |
| One induction course | 12 (6.9) |
| Two induction courses | 36 (20.7) |
| Relapse | 126 (72.4) |
| <6 months | 48 (27.6) |
| ≥6 months | 78 (44.8) |
| Duration of CR/CRi before relapse (months): | |
| Median (IQR) | 7.7 (4.7–12.6) |
| Previous allogeneic HSCT in first CR: n (%) | 29 (23.0) |
| FLT3 ITD/wt ratio (N = 65) (%): | |
| Median (IQR) | 50.0 (28.0–68.0) |
| Co-mutations: n (%) | |
| NPM1 mutations | |
| Yes | 94 (56.6) |
| No | 72 (43.4) |
| DNMT3A mutations | |
| Yes | 20 (29.9) |
| No | 47 (70.1) |
| CEBPA mutations | |
| Yes | 6 (7.4) |
| No | 75 (92.6) |
| IDH1/2 mutations | |
| Yes | 8 (9.4) |
| No | 77 (90.6) |
| N/K RAS mutations | |
| Yes | 3 (8.6) |
| No | 32 (91.4) |
| WBC (×109/L): | |
| At diagnosis (refractory) | |
| Median (IQR) | 72.8 (18.3–149.8) |
| Range | 0.6–317.0 |
| At relapse | |
| Median (IQR) | 7.4 (3.4–26.9) |
| Range | 0.1–436.0 |
CR: complete remission; CRi: CR with incomplete hematological recovery; HSCT: hematologic stem cell transplantation; IQR: interquartile range; WBC: white blood cells count; wt: wild-type.